Alpha 2.0
Login Register
» Authors » Jorge Alatorre-Alexander

Jorge Alatorre-Alexander

Explore the profile of Jorge Alatorre-Alexander including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 15
Citations 944
Followers 0
Related Specialties
Oncology
Pulmonary Medicine
General Medicine
Top 10 Co-Authors
Tony Mok
Solange Peters
Niels Reinmuth
Sang-We Kim
Haruhiro Saito
Maen Hussein
Edward B Garon
Sarayut Lucien Geater
Byoung Chul Cho
Farah Louise Lim
Published In
J Thorac Oncol
J Clin Oncol
J Immunother Cancer
BMC Cancer
Urol Case Rep
Affiliations
Soon will be listed here.
Recent Articles
1.
Durvalumab With or Without Tremelimumab in Combination With Chemotherapy in First-Line Metastatic NSCLC: Five-Year Overall Survival Outcomes From the Phase 3 POSEIDON Trial
Peters S, Cho B, Luft A, Alatorre-Alexander J, Geater S, Laktionov K, et al.
J Thorac Oncol . 2024 Sep; 20(1):76-93. PMID: 39243945
Introduction: The primary analysis (median follow-up 34.9 mo across all arms) of the phase 3 POSEIDON study revealed a statistically significant overall survival (OS) improvement with first-line tremelimumab plus durvalumab...
2.
Amivantamab plus Lazertinib in Previously Untreated -Mutated Advanced NSCLC
Cho B, Lu S, Felip E, Spira A, Girard N, Lee J, et al.
N Engl J Med . 2024 Jun; 391(16):1486-1498. PMID: 38924756
Background: Amivantamab plus lazertinib (amivantamab-lazertinib) has shown clinically meaningful and durable antitumor activity in patients with previously untreated or osimertinib-pretreated (epidermal growth factor receptor)-mutated advanced non-small-cell lung cancer (NSCLC). Methods:...
3.
A Brief Report of Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: Outcomes by Tumor PD-L1 Expression in the Phase 3 POSEIDON Study
Garon E, Cho B, Luft A, Alatorre-Alexander J, Geater S, Trukhin D, et al.
Clin Lung Cancer . 2024 Apr; 25(3):266-273.e5. PMID: 38584069
No abstract available.
4.
High-dose alectinib for fusion-positive non-small cell lung cancer in the Blood First Assay Screening Trial
Dziadziuszko R, Peled N, Mok T, Peters S, Aix S, Alatorre-Alexander J, et al.
Contemp Oncol (Pozn) . 2024 Feb; 27(4):217-223. PMID: 38405208
Introduction: This paper presents results from Cohort B (rearranged during transfection [], fusion-positive) of the Blood First Assay Screening Trial in patients with advanced non-small cell lung cancer (NSCLC) screened...
5.
Patient-reported outcomes with durvalumab, with or without tremelimumab, plus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer (POSEIDON)
Garon E, Cho B, Luft A, Alatorre-Alexander J, Geater S, Kim S, et al.
Lung Cancer . 2023 Nov; 186:107422. PMID: 37992595
Objectives: In the phase 3 POSEIDON study, first-line tremelimumab plus durvalumab and chemotherapy significantly improved overall survival and progression-free survival versus chemotherapy in metastatic non-small-cell lung cancer (NSCLC). We present...
6.
Final results from TAIL: updated long-term efficacy of atezolizumab in a diverse population of patients with previously treated advanced non-small cell lung cancer
Ardizzoni A, Azevedo S, Rubio-Viqueira B, Rodriguez-Abreu D, Alatorre-Alexander J, Smit H, et al.
J Immunother Cancer . 2022 Nov; 10(11). PMID: 36450379
In patients with previously treated advanced or metastatic non-small cell lung cancer (NSCLC), atezolizumab therapy improves survival with manageable safety. The open-label, single-arm phase III/IV TAIL study (NCT03285763) evaluated atezolizumab...
7.
Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: The Phase III POSEIDON Study
Johnson M, Cho B, Luft A, Alatorre-Alexander J, Geater S, Laktionov K, et al.
J Clin Oncol . 2022 Nov; 41(6):1213-1227. PMID: 36327426
Purpose: The open-label, phase III POSEIDON study evaluated tremelimumab plus durvalumab and chemotherapy (T + D + CT) and durvalumab plus chemotherapy (D + CT) versus chemotherapy alone (CT) in...
8.
Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial
Marconi V, Ramanan A, de Bono S, Kartman C, Krishnan V, Liao R, et al.
Lancet Respir Med . 2021 Sep; 9(12):1407-1418. PMID: 34480861
Background: Baricitinib is an oral selective Janus kinase 1/2 inhibitor with known anti-inflammatory properties. This study evaluates the efficacy and safety of baricitinib in combination with standard of care for...
9.
Blood First Assay Screening Trial (BFAST) in Treatment-Naive Advanced or Metastatic NSCLC: Initial Results of the Phase 2 ALK-Positive Cohort
Dziadziuszko R, Mok T, Peters S, Han J, Alatorre-Alexander J, Leighl N, et al.
J Thorac Oncol . 2021 Jul; 16(12):2040-2050. PMID: 34311110
Introduction: The Blood First Assay Screening Trial is an ongoing open-label, multicohort study, prospectively evaluating the relationship between blood-based next-generation sequencing (NGS) detection of actionable genetic alterations and activity of...
10.
Primary results from TAIL: a global single-arm safety study of atezolizumab monotherapy in a diverse population of patients with previously treated advanced non-small cell lung cancer
Ardizzoni A, Azevedo S, Rubio-Viqueira B, Rodriguez-Abreu D, Alatorre-Alexander J, Smit H, et al.
J Immunother Cancer . 2021 Mar; 9(3). PMID: 33737339
Background: Atezolizumab treatment improves survival, with manageable safety, in patients with previously treated advanced/metastatic non-small cell lung cancer. The global phase III/IV study TAIL (NCT03285763) was conducted to evaluate the...